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Abstract. The pituitary gland is an organ that functionally 
connects the hypothalamus with the peripheral organs. The 
pituitary gland is an important regulator of body homeostasis 
during development, stress, and other processes. Pituitary 
adenomas are a group of tumors arising from the pituitary 
gland: they may be subdivided in functional or non-functional, 
depending on their hormonal activity. Some trophic and neuro-
trophic factors seem to play a key role in the development and 
maintenance of the pituitary function and in the regulation of 
hypothalamo-pituitary-adrenocortical axis activity. Several 
lines of evidence suggest that trophic and neurotrophic 
factors may be involved in pituitary function, thus suggesting 
a possible role of the trophic and neurotrophic factors in the 
normal development of pituitary gland and in the progression 
of pituitary adenomas. Additional studies might be necessary 
to better explain the biological role of these molecules in the 
development and progression of this type of tumor. In this 
review, in light of the available literature, data on the following 
neurotrophic factors are discussed: ciliary neurotrophic 
factor (CNTF), transforming growth factors β (TGF-β), glial 
cell line-derived neurotrophic factor (GDNF), nerve growth 
factor (NGF), vascular endothelial growth factor (VEGF), 
vascular endothelial growth inhibitor (VEGI), fibroblast 
growth factors (FGFs) and epidermal growth factor (EGF) 
which influence the proliferation and growth of pituitary 
adenomas.
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1. Introduction
The pituitary gland is an organ that physiologically connects 
the hypothalamus with the peripheral organs. The pituitary 
gland is an important regulator of body homeostasis during 
development, stress, and other physiological processes. This 
small organ is localized in a tiny cavity called sella turcica. 
The pituitary fossa is a depression in the bone structure at the 
base of the brain.
The pituitary is functionally and anatomically connected 
to the hypothalamus by the median eminence. The gland 
receives blood through the hypophyseal portal circulation, 
which carries the hypothalamic hormones to the specialized 
adenohypophyseal cells.
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The pituitary gland is composed by adenohypophysis (or 
anterior pituitary) and neurohypophysis (or posterior pituitary) 
that are two different lobes. The adenohypophysis contains 
three regions: the pars tuberalis (pars infundibularis), the pars 
intermedia (intermediate lobe) and pars distalis (also known 
as the anterior lobe). The pars intermedia is placed in the 
marginal area between the anterior pituitary and the poste-
rior pituitary. The pars distalis represents the largest part of 
the adenohypophysis while the intermediate lobe is a small 
portion of the gland. The different cells of pituitary gland 
secrete many molecules: endocrine hormones, cytokines and 
growth factors.
The neurohypophysis, or posterior pituitary, is character-
ized by axonal terminals of the hypothalamic supraoptic and 
paraventricular (PVN) nuclei. The neurohypophysis contains 
the pituicytes: fusiform cells related with microglia. The 
pituicytes surround the axons influencing the secretion of 
neurohypophyseal hormones (1) as oxytocin and vasopressin.
Hypothalamic stimulatory and inhibitory factors and 
other molecules interact with the auto- and paracrine factors 
to induce transcriptional regulation, translation and secre-
tion of the pituitary hormones. Hormones released by the 
anterior pituitary are produced by specialized cells. Growth 
hormone (GH) is produced by somatotroph, prolactin (PRL) 
by lactotrophs, adrenocorticotropic hormone (ACTH) by 
corticotrophs, thyroid-stimulating hormone (TSH) by thyreo-
trophs, luteinizing hormone (LH) and follicle-stimulating 
hormone (FSH) by gonadotrophs cells. The function of the 
specialized cells is influenced by the interaction between cells 
via systemic signals.
The lactotrophs are the cells located in the anterior pitu-
itary and they interact with the gonadotrophs to improve the 
paracrine secretion. Gonadotrophs are in the pars distalis and 
tuberalis, while thyrotrophs, that represent a small section of 
the total pituitary cells, are found in the anterior-medial part of 
the pituitary gland and they secrete the subunits of PRL, LH, 
and FSH. In the central mucoid wedge of the pituitary gland, 
we can observe the presence of corticotrophs that constitute 
15-20% of the adenophypophyseal cells (2). Folliculostellate 
cells (FS) represent a small rate of total population of pituitary 
cells. Some immunohistochemical studies described the pres-
ence of molecular connections between the FS cells in anterior 
gland (3,4). FS cells in the normal pituitary tissue secrete large 
amounts of VEGF (5,6) that improve blood vessel system of 
the gland (7).
The hypophysis may be affected by different pathologies 
causing endocrine and neurological disorders. Among these 
pathologies there are craniopharyngioma, pituicytoma and 
granular cell tumor, chordoma and the pituitary adenomas 
that are associated with endocrine dysfunctions such as 
Cushing's disease or acromegaly. Some pituitary neoplasms 
are simulated by pathological conditions as lymphocytic or 
granulomatous hypophysitis.
Craniopharyngiomas are relatively uncommon tumors 
and arise in the suprasellar region. They are believed to be 
congenital. Craniopharyngiomas involve the pituitary gland 
and they can modify the endocrine functions and damage 
optical nerves and chiasm, causing vision problems (8).
The pituicytoma is a rare neoplasm in the posterior pituitary 
gland that arises in the infundibulum or the neurohypophyseal 
cells. A possible development of this tumor was also noticed 
from the FS cells. In a recent study, a positivity for vascular 
endothelial growth factor (VEGF) was detected in patients 
with pituicytoma (9).
Granular cell tumors (GCTs) can arise in different regions 
of the body: skin, head and neck. GCTs occur rarely in the 
central nervous system developing in the posterior hypophysis 
and cerebral hemispheres (10,11).
Intracranial chordomas are characterized by soft and 
gelatinous lesions usually developing at the dorsum sellae. 
The cells are large and vacuolated. Chordomas may produce 
compression of the pituitary and destruction of the pituitary 
fossa. These lesions slowly reach neurovascular bundles and 
often cannot be treated surgically (12).
Pituitary adenomas constitute a common group of benign 
tumors arising in adenohypophyseal cells of the anterior lobe 
of the pituitary gland (13,14). Some adenomas are similar to 
malignant tumors, invading the cavernous sinus, sphenoid 
sinus and hypothalamus (15). The invasive adenomas are 
characterized by large size, rapid growth and scarce response 
to treatment. Pituitary adenomas may be subdivided to 
functional and non-functional, depending on their hormonal 
activity in vivo (14,16,17).
Tumors may hypersecrete pituitary hormones which can 
determine endocrine disturbances of physiological mecha-
nisms that are controlled by the gland. The pituitary adenomas 
can produce great doses of GH causing gigantism or acro-
megaly, ACTH leading to Cushing's disease and PRL, which 
negatively influences reproduction. Some very rare pituitary 
adenomas secrete FSH and LH (which cause reproductive 
dysfunction) or TSH that leads to hyperthyroidism. However, 
some pituitary tumors do not produce hormones, but their 
growth and expansion may produce a reduced function of the 
gland (hypopituitarism). Non-functioning pituitary adenomas 
represent ~30% of all pituitary tumors (18). Non-functioning 
pituitary adenomas may be characterized by the feature of 
invasive macroadenomas that determine the onset of neuro-
logical symptoms (19).
Regarding the different therapeutic approaches, which 
include trans-sphenoidal resection, pharmacotherapy, and 
radiation therapy, the results remain inadequate in a signifi-
cant number of patients (20,21). The invasiveness of pituitary 
adenomas seems to be an important determinant for the 
success rate of surgical treatment. Generally, this tumor has 
no capsule that could separate it from the adjacent tissue and, 
consequently, the growing adenoma can reach and invade the 
adjacent structures (22). Such adenomas may produce some 
symptoms through two mechanisms: i) hypersecretion or 
hyposecretion of hormones and i) compression exerted on the 
neighbouring structures (23). Functioning pituitary adenomas 
become symptomatic because they lead to hormone secretion 
whereas the non-functioning variety may grow slowly and 
compress the optic chiasm situated directly above the pituitary 
gland, producing progressive visual loss (24).
Actually, the causes responsible for the pathogenic 
processes of initiation, expansion and invasion of pituitary 
tumors are not clear, but different mechanisms are involved 
in the pituitary tumorigenesis. A small percentage of tumors 
is hereditary and so these tumors may be due to genetic muta-
tions (20). Recent studies suggest that neurotrophins and other 
INTERNATIONAL JOURNAL OF ONCOLOGY  51:  1014-1024,  20171016
growth factors play a significant role in pituitary adenoma 
development (25-29) (Table I). In this review we summarize 
and discuss the data regarding the trophic and neurotrophic 
factors which seem to influence the proliferation and growth 
of pituitary adenomas.
2. Ciliary neurotrophic factor (CNTF)
The CNTF is a neurotrophin of the IL-6 family and has 
important neuroprotective effects on neurons. CNTF acts 
by binding to several receptors: CNTF receptor (CNTFR), 
gp130 and the leukemia inhibitory factor receptor (LIFR). The 
resultant CNTF-CNTFRα complex induces the formation of 
the LIFRα-gp130 heterodimer. When CNTF interacts with 
the receptors it activates the Janus kinases/signal transducer 
and activator of transcription (JAk/STAT), mitogen-activated 
protein kinase (MAPk), and phosphatidyl inositol 3-kinase/
protein kinase b (PI3k/Akt) signalling pathways (30). Some 
studies found that the deletion of the CNTF gene in mice deter-
mines the degeneration of motor neurons and the increasing 
of an inflammatory demyelinating disease (31,32). The CNTF 
have been demonstrated to be important for autocrine and 
paracrine mechanisms that act in the pituitary gland (33). 
CNTF is expressed in folliculostellate cells and in lactoso-
matotropic cells and its secretion stimulates the production of 
GH and PRL (34,35).
Some authors observed that folliculostellate and lactoso-
matotrophic cells express the mRNA of CNTF (34) and the 
mRNA of the α-chain specific for the CNTFR. This mRNA 
for the CNTFR was detected in tumors secreting PRL, GH 
and in non-functioning tumors (35). CNTFR are expressed 
on lactotropic, somatotropic and non-functioning pituitary 
adenomas demonstrating that these receptors are also present 
on human pituitary cells. CNTFR was seen to be involved in 
pituitary pathophysiology (35). In particular, CNTF did not 
influence the secretion of either GH or PRL and on GH mRNA 
in monolayer cell cultures obtained from normal rat anterior 
pituitary. However, CTNF significantly stimulated both PRL 
and GH secretion when the cells were amassed in cultures, 
restoring the three-dimensional structure of the cells. These 
results underline that the three-dimensional structure of the 
pituitary cells represents a key role for the regulatory action of 
CTNF in anterior pituitary cells (35). The three-dimensional 
organization of the cells constitutes their physiological confor-
mation that can also result in a better expression of receptors. 
It was also observed that the interaction of hormone-secreting 
cells with the extracellular matrix is determining the role of 
CNTF in regulation of GH and PRL in producing the pituitary 
cells.
3. Transforming growth factors β (TGF‑β)
TGF-β is a suppressor or a promoter of tumor development in 
relation to the tumor stage and type (25,36). TGF-β signalling 
starts through the binding of some ligands (TGF-β1, TGF-β2 
and TGF-β3) with type II TGF-β receptors (TGF-β RII): 
subsequently the recruitment of type I TGF-β receptor 
(TGF-β RI) forms a complex (37-39). Moreover, TGF-β RII 
phosphorylates TGF-β RI to activate it (37-39). TGF-β signal 
transducer proteins are Smads and the activated TGF-β 
receptor complexes can phosphorylate Smad2 and Smad3. 
These proteins bind Smad4 to form a complex that regulates 
the transcriptional activity. On the other hand, Smad7 is an 
inhibitory protein that suppresses the phosphorylation of 
Smad2 and Smad3 (40-42). Some authors reported that Smad3 
and phospho-Smad3 are potential markers of invasive non-
functioning pituitary adenomas. In particular, it was observed 
that the invasion of non-functioning pituitary adenoma is 
Table I. List of abbreviations.
Adrenocorticotropic hormone ACTH Melanoma-associated antigen 3  MAGEA3
Protein kinase b AkT Mitogen-activated protein kinase  MAPk
Ciliary neurotrophic factor CNTF Nerve growth factor  NGF
Death receptor-3  DR-3 Nuclear factor κb NF-κb
Decoy receptor-3  DcR-3 p75 neurotrophin receptor  p75NTR
Epidermal growth factor  EGF Parkinson's disease  PD
Fibroblast growth factors  FGFs Phosphatidyl inositol 3-kinase PI3k
Follicle-stimulating hormone  FSH Pituitary tumor-derived FGFR4  Ptd-FGFR4
Glial cell line-derived neurotrophic factor  GDNF Prolactin  PRL
Glycosyl phosphatidyl inositol-linked protein  GFRa1 Tropomyosin-related kinase A  TrkA
Granulocyte-macrofage colony-stimulating factor GM-CSF Tyrosine kinase receptor  RET
Growth hormone  GH Signal transducer and activator of transcription  STAT
Human type-α transforming growth factor  hTGF-α Small mother against dacapentaplegic Smad
Interferon γ IFN-γ Thyroid-stimulating hormone  TSH
Janus kinases  JAK Transforming growth factors β  TGF-β
Jun N-terminal kinase  JNk Vascular endothelial growth factor  VEGF
Leukemia inhibitory factor receptor  LIFR Vascular endothelial growth inhibitor  VEGI
Luteinizing hormone  LH Vascular endothelial growth factor receptors  VEGFR
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associated with low level of expression of Smad3 and phospho-
Smad3 and that proliferative activity was higher in invasive 
non-functioning pituitary adenomas when compared to non-
invasive non-functioning pituitary adenomas (43).
The clinical importance of TGF-β ligands and down-
stream signalling mediators has been analyzed in some 
studies performed in different types of tumors although the 
results obtained are discordant (37-39). In non-functioning 
pituitary adenomas, the expression of mRNA TGF-β1 levels 
was significantly lower than in invasive non-functioning pitu-
itary adenomas and in non-invasive non-functioning pituitary 
adenomas, in comparison to normal anterior pituitaries (43). It 
has been suggested that the invasiveness of pituitary adenomas 
could be predicted by TGF-β1 blood serum concentration (44). 
Some studies widely evaluated the role of the TGF-β1 gene in 
some tumors. The expression of this gene was studied in subjects 
with breast cancer and a relationship was found between 
TGF-β1 gene and a poorer patient clinical outcome (45). The 
evaluation of a tumor in lung cell lines, established that this 
gene plays an important role in cell proliferation (46). TGF-β1 
is commonly evaluated in tumors: in fact, the in vitro studies 
were performed on TGF-β1 function in cancer cell lines other 
than lung cancer and pituitary adenoma cells (47).
A study described the development of prolactinomas 
in transgenic female mice with pituitary TGF-α transgene 
expression (48). The levels of pituitary TGF-α mRNA become 
high before initiation of lactotroph hyperplasia. TGF effects 
are increased in vivo conditions by estrogen, and TGFs do not 
seem to improve other pituitary cell type cancers.
4. Glial cell line‑derived neurotrophic factor (GDNF)
GDNF is a component of a large family of neurotrophic 
factors that include GDNF, Neurturin, Artemin, and 
Persephin (49,50). GDNF plays a crucial role in the develop-
ment and survival of various neuronal populations (51,52). 
However, the intracellular trafficking mechanisms of GDNF 
are not fully understood. Some studies demonstrated that 
although GDNF is not essential for the development of 
dopaminergic neurons (49,50), the presence of GDNF is 
important for the maintenance of these cells in A9 dopami-
nergic neurons of tyrosine kinase receptor (RET) knockout 
mice (51). In fact, degeneration of A9 neurons is evident in 
Parkinson's disease (PD) and GDNF was retained to be a 
possible therapeutic drug for PD. The signalling of GDNF 
is mediated through a system including GFRa1 which binds 
to GDNF. Subsequently, this complex binds and triggers the 
RET (52,53). Recently, GDNF and RET gene expression have 
been found in anterior pituitary glands from male rats (54). 
In an interesting study, a positive immunostaining for GDNF 
was observed in all of the GH-secreting pituitary adenomas 
and in 10% of the corticotropinomas (55). Some experimental 
evaluations showed that both RET and GDNF are normally 
secreted in the human pituitary gland. These results were 
confirmed through other experimental techniques, demon-
strating that the pituitary gland produces GDNF and that 
the gland itself is also a target tissue of neurotrophins (55). 
GDNF is mostly present in somatotrophs and, to a lesser 
extent, in corticotrophs, but it is not present in gonadotrophs 
of the human pituitary gland (55). In particular, a positive 
immunostaining for GDNF was observed in all of the GH 
secreting adenomas and in 10% of the corticotropinomas, but 
it was negative in all other pituitary tumors.
5. Nerve growth factor (NGF)
NGF is a growth factor expressed by peripheral tissues that 
are innervated by sensory and sympathetic neuronal projec-
tions and it belongs to the nerve growth factor family of 
neurotrophins. NGF controls neuronal survival, differentiation 
and growth binding to two receptors: the p75 neurotrophin 
receptor (p75NTR) and tropomyosin-related kinase A (TrkA) 
(56-58). Some studies have demonstrated that NGF is involved 
in tumor progression, increasing cancer cell survival and 
proliferation (59-61). NGF is not only described in the nervous 
system, but also in some normal and neoplastic human 
tissues (62,63). In the submandibular gland of the mouse NGF 
is composed of 2α subunits, 1β subunit, 2γ subunits (α2βγ2) 
and also one or two zinc ions (64). The β subunit of NGF 
represents a biologically active region, the 2γ subunits of NGF 
have proteolytic activity and the 2α subunits do not possess 
enzymatic activity (65-67).
NGF acts as a regulator of neuronal survival, prolifera-
tion, and differentiation in the peripheral and central nervous 
systems by binding to its receptors: TrkA and p75NTR. The 
binding between p75NTR and NGF controls the activation of 
c-Jun N-terminal kinase (JNk) signalling pathways to promote 
apoptosis, and the activation of nuclear factor κb (NF-κb) 
pathways to promote cell survival. Moreover, NGF increases 
cell proliferation and metastasis binding to TrkA (68,69). 
Some researchers have also found that p75NTR may help to 
improve the binding of NGF with TrkA, TrkA activation and 
the number of binding sites (70). TrkA regulates growth and 
differentiation of neurons in peripheral and central nervous 
systems (71). NGF facilitates the development of perivascular 
nerves to regulate the blood flow in tumors. NGF may promote 
angiogenesis by interacting with α9β1 integrin (72). In one 
study it was observed that p75NTR in tumor cells may nega-
tively regulate cell growth and proliferation (73). An increased 
apoptosis (pro-apoptotic effect) was demonstrated in cells 
with a high expression of p75NTR from patients with medul-
loblastoma (74). In prolactinoma cells, NGF binds p75NTR 
and activates NF-κb in a TrkA-independent way (75). It 
was observed that TrkA triggers proliferation in some tumor 
cells (76,77), but inhibits cell growth in other tumors (78,79). 
In some patients with pituitary adenomas, a moderate expres-
sion for NGF, and its relative receptor TrkA and p75NTR were 
observed on epithelial glands (29) (Fig. 1). It has also been 
found that p75NTR suppresses some tumors (80,81), but has 
a mitogenic effect in others (82). The cell cycle controls the 
cell proliferation and the G1 phase of the cycle is regulated by 
the protein p53 that is a tumor suppressor (83). Inactivation of 
this pathway influences tumorigenesis. Some mutations that 
inactivate the p53 gene are observed in more than 50% of all 
human cancers (84). However, p53 is rarely mutated in human 
pituitary adenomas (85). Mammosomatotroph pituitary cells 
express NGF and its receptors. Mice, in which transgenic NGF 
is driven by the prolactin promoter, develop lactotroph hyper-
plasia without adenomas, despite having markedly enlarged 
pituitary glands (86).
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6. Vascular endothelial growth factor (VEGF)
VEGF is a central regulatory protein of angiogenesis with a 
hydrophobic leader sequence. It has a homodimeric structure 
with three intramolecular and two intermolecular disulfide (S-S) 
bonds. It is a member of a family that exerts important func-
tions in vasculogenesis, angiogenesis and lymphangiogenesis. 
It was found that VEGF is a tumor-secreted protein that can 
increase microvascular permeability to plasma proteins. 
In particular, it improves vascular permeability to plasma 
and plasma proteins, a typical characteristic of the tumor 
microvasculature and a critical early step in cancer stroma 
generation. VEGF is overexpressed in the cells of several 
human vascular tumors of the brain, colon, gastrointestinal 
tract, ovary, and breast (87). Some studies found that VEGF 
may not directly participate to tumoral invasion, but it may 
regulate pathways that increase tumor volume or invasiveness 
(88-91). Results obtained in a study, described that VEGF 
operates as a neurotrophic factor and plays an important role 
during the regeneration of peripheral nerves (92).
VEGF binds and activates the type 1 and 2 vascular 
endothelial growth factor receptors (VEGFR1 and VEGFR2) 
on the vascular endothelium (93). In the pituitary VEGF and 
VEGFR2 are expressed (94,95). Various experimental publica-
tions reported that VEGF expression is not necessarily related 
to endothelium and vessels, but it is also found in adenoma 
cells (28,96). Distribution and location of VEGF receptors in 
pituitary adenomas has also been studied. A relevant expression 
of fetal liver kinase-1, a type of VEGF receptor that controls 
mitogenesis and influences endothelial cell characteristics, 
may have a potential role in the pituitary tumorigenesis (97). 
According to this observation fetal liver kinase-1 expression 
was very marked in non-functioning adenomas in comparison 
to functioning tumors (97). Other reports concerning the 
expression and the distribution of VEGF and its receptors in 
pituitary adenomas are not conclusive. In another study, VEGF 
expression was recognized as different in the subtypes, thus 
suggesting possible different modalities of VEGF expression 
and/or effects (28). The tyrosine kinase receptors of VEGF are 
mainly expressed on vascular endothelium, and it behaves as a 
selective mitogen for vascular endothelium.
VEGF contributes to the formation of the vascular network 
of a new pituitary tumor (98,99) and is also involved in the 
proliferative action of estrogen on lactotrophs (100), VEGF 
might contribute to adequate temporal vascular supply. It 
was observed that VEGF is expressed in all cell types of the 
pituitary, but mainly in somatotrophic and follicle-stellate 
cells. In the normal human pituitary gland, VEGF expres-
sion was higher than adenomas (28). One study found no 
differences in VEGF expression among tumors of different 
histotypes (101). Also, comparing VEGF in different types, 
the highest expression was observed in non-functioning 
adenomas and GH producing adenomas (97). Elevated serum 
VEGF levels have been determined in patients with pituitary 
tumors and VEGF secretion was measured in human pituitary 
tumors cultured in vitro. In a group of patients with pituitary 
adenomas it was observed that VEGF protein expression was 
higher in dopamine agonist resistant prolactinomas compared 
to non-functioning GH and ACTH secreting adenomas (102). 
Different VEGF levels in ACTH-secreting adenomas may be 
produced by glucocorticoids which are efficient inhibitors of 
VEGF secretion (103). VEGF targeting in pituitary adenomas 
may be useful as shown in a study performed on mice (104).
The VEGF is characterized from several variants of the 
growth factor that can bind one of the three VEGF-specific 
receptor tyrosine kinases to influence angiogenesis or related 
processes (105). The VEGF secretion is increased by hypoxia 
of the tumor. The deficiency of oxygen increases the expres-
sion of hypoxia-inducible factor 1 (HIF1), which enhances the 
VEGF expression.
7. Vascular endothelial growth inhibitor (VEGI)
VEGI is a protein member of the TNF superfamily that can 
inhibit the proliferation of endothelial cells and exerts an anti-
angiogenic effect on the endothelial cells (106). VEGI is mainly 
produced by vessel endothelial cells and also be expressed on 
antigen-presenting cells and lymphocytes such as T cells and 
dendritic cells. VEGI always acts as a co-stimulator to induce 
T cell proliferation and cytokine secretion (107,108). VEGI 
acts by interacting with two receptors: death receptor-3 (DR-3) 
and the decoy receptor-3 (DcR-3). DR-3 is also known as 
Figure 1. (A) Micrographs of NGF-TrkA-P75 immunostaining in GH-secreting pituitary adenomas. NGF immunoreactivity was moderate (arrows) in the epi-
thelial compartment of the neoplastic area, weak in the extracellular matrix and totally absent in the vessel endothelium (x40). (b) P75NTR immunoreactivity 
was weak (arrows) in the epithelial neoplastic cells and in the extracellular matrix, but totally absent in the vessel endothelium (x40). (C) Immunoreaction for 
TrkA was moderate in the nucleus of the neoplastic cells (arrows), weak in the extracellular matrix and totally absent in the vessel endothelium (x40).
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TNFRSF25: this receptor is a protein of approximate 47 kDa 
in size and is a member of the TNF receptor superfamily. So 
far DR3 is the only known functional receptor for VEGI and 
its role is to induce apoptosis after activation.
Many studies have shown that VEGI is related to various 
diseases including bowel diseases (109), lung cancer (110), 
prostate cancer (111), breast cancer (112) and pituitary 
adenomas (27). The authors of these studies described how 
VEGI expression is decreased in late stage tumors and is 
associated with survival of patients. VEGI and other factors 
may influence the development of diseases through the 
involvement of some pathways (Fig. 2). It was recently found 
that VEGI has a direct effect on both epithelial and cancer 
cells, also by exerting an inhibitory effect on the migration and 
growth of neoplastic cells. Some results indicated that VEGI 
plays an essential role in activating the transcription factor 
κb and caspase-3 (113). Other studies suggested that VEGI 
may also be involved in the immune response by inducing the 
secretion of granulocyte-macrofage colony-stimulating factor 
(GM-CSF) and interferon γ IFN-γ (114). VEGI gene expres-
sion also decreases inflammation and angiogenesis in cancers 
or wounds (114). Studies that involved the cell cycle suggested 
that VEGI maintained early G1 arrest in the G0/G1 cells and 
induced programmed death in the endothelial cell cycle (115).
Pituitary tumors with cystic lesions tended to express low 
levels of VEGI and, in particular, pituitary tumors that invade 
the floor of the sella turcica showed reduced levels of VEGI. 
VEGI has an anti-angiogenesis function and some studies 
demonstrated that it acts as a powerful angiogenesis inhibitor. 
Lack of VEGI was negatively correlated with angiogenesis in 
solid tumors, due to the removal of the inhibitory mechanisms 
in the tissues (116,117). In pituitary adenomas, VEGI inhibits 
the growth and the migration of tumor cells through DR3 (113). 
In particular, high levels of VEGI and DR3 were found to be 
associated with intratumoral haemorrhage. It is thus argued 
that, in a similar pattern, the lack of VEGI in pituitary tumors 
may trigger an increase in angiogenesis within the tumor 
tissues.
8. Fibroblast growth factors (FGFs)
FGFs are a family of molecules that control the differen-
tiation, migration, and angiogenesis of the cells (118,119). 
FGFs includes 23 ligands and FGF2 is the basic FGF, which 
regulates the production of pituitary hormones and the prolif-
eration and differentiation of parenchyma and vessels (120). 
FGF2 isoform of 18 kDa is highly secreted in the normal 
human pituitary gland, whereas the 24 kDa isoform is largely 
secreted by pituitary adenomas (121). It was observed that 
high levels of FGF2 were expressed in patients with pituitary 
neoplasms and the secretion decreased after surgical adeno-
mectomy (122). In a recent study, it was found that FGF2 is 
secreted in different types of pituitary tumors, including GH 
secreting adenomas (123). FGF2 expression was significantly 
higher in patients without postoperative remission observed at 
the third month and later, if compared to subjects with remis-
sion (123). Also, the levels of FGF2 were higher in patients who 
presented a sphenoid bone invasion if compared to patients 
without bony lesions (123).
The interaction between FGF2 and some transmembrane 
receptors (FGFRs) with tyrosine kinase activity, determines 
the biological effects of FGF2 (124). The FGFRs are encoded 
Figure 2. Autocrine and paracrine secretion of trophic factors and their influence on intracellular and extracellular compartments.
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by different genes to obtain multiple isoforms, also the FGFRs 
are expressed in the membrane surfaces of different type of 
cells, including endothelial cells in which FGF2 influences 
the angiogenic development. Each FGFR is characterized by 
three Ig-like extracellular domains, a transmembrane domain, a 
tyrosine kinase cytoplasmic domain and a -COOH domain that 
comprehends a group of tyrosines phosphorylated by the binding 
with the ligand (125,126). A great percentage of FGFs shows a 
specific affinity for the receptor isoforms. It was observed that 
FGFRs are expressed in different types of tumors, including 
pituitary adenomas (127-132). In particular, FGFR1 was highly 
expressed in pituitary adenomas compared to healthy gland 
(132) and the cytoplasmic immunoreactivity of the receptor was 
inversely correlated with pituitary lesion size (133).
A study has demonstrated the lack of FGFR2 in the 
pituitary adenomas that causes the upregulation of the mela-
noma-associated antigen 3 (MAGEA3) (134). The presence of 
arginine at codon 388 of the FGFR4 gene, which encodes the 
receptor, was associated with the phosphorylation process of 
mitochondrial STAT3 serine that improves the GH secretion 
in pituitary cells promoting tumorigenesis development (135). 
Also, this arginine allele was associated with other forms of 
tumors resistant to the pharmacological treatment (136-139). 
The expression of FGFR isoforms was really modified in 
pituitary adenomas (140). It was observed that the modified 
FGFR4 expression in pituitary tumors is caused by the pitu-
itary tumor-derived FGFR4 (ptd-FGFR4) (141). This is an 
isoform with a deletion at the N-terminal produced by substi-
tute transcription initiation (141,142). The FGFR4 isoforms 
have a different capability to link the cell adhesion molecules 
and, in particular, ptd-FGFR4 blocks cell adhesion interacting 
with N-cadherin signaling (143). The complex constituted 
by FGFR4 and N-cadherin may be considered an important 
therapeutic target to reduce the growth and the invasiveness of 
tumor cells (143).
9. Epidermal growth factor (EGF)
EGF is a small protein of 6 kDa containing 53 amino acids 
which comprises three disulfide bridges (144). EGF displays 
a homology of function and sequence with human type-α 
transforming growth factor (hTGF-α), which can link the EGF 
receptor sites. EGF is characterized by mitogenic activity and 
so it is involved in the process of cell growth and tumorigen-
esis. In fact, EGF is a protein contained in a network of growth 
factors and receptors that controls the growth and the division 
of cells. EGF is produced by pituitary cells and it acts as a 
growth factor, stimulating prolactin synthesis (145). In human 
pituitary gland EGF is localized mainly in thyrotrophic and 
gonadotrophic cells (145). An immunohistochemical study 
described the EGF expression in functional and non-functional 
pituitary adenomas (145).
It was observed that EGF can promote the transphos-
phorylation of the related oncogene neu through the binding 
with epidermal growth factor receptor (EGF-R) (146). EGF-R 
is a 170-kDa transmembrane glycoprotein constituted by: 
a tyrosine kinase domain, a transmembrane domain and an 
extracellular domain of binding. EFG-R is a component of a 
family which includes four known members and it is consid-
ered the homolog of the v-erbb oncogene protein (147). Some 
studies evidenced EGF-R overexpression in different tumors: 
lung (148), breast (149), ovarian (150) and gastric (151) cancers. 
Different studies observed a higher expression in non-func-
tional pituitary tumors (152-154). Interestingly, Onguru et al 
described a moderate or a strong positivity of EGFR in more 
than 50% of adenomas (154). In each group of adenomas the 
percentage of EGFR overexpression was variable and it was 
higher in non-functional compared to functional adenomas.
Also, in ACTH secreting adenomas the lowest number of 
tumors expressing EGFR was detected (154). However, high 
expression of EGFR is frequently found in ACTH secreting 
adenomas, in which EGF signaling is deleted and consequently 
there is inhibition of ACTH secretion (155,156). The binding 
between intracellular EGFR domain and its specific antibody 
showed an immunoreactivity in corticotroph adenomas and 
many cells of ACTH secreting tumors were EGFR immu-
noreactive (157). Also, a low or absent immunoreactivity 
was observed for p27 protein that blocks the cell cycle (157). 
Probably, EGFR promotes the signaling activation that induces 
the downregulation of p27, which promotes tumorigenesis by 
the stimulation of ACTH secretion (158).
10. Conclusion
Pituitary adenomas are common tumors that are classi-
fied on the basis of certain characteristics: size, invasion of 
adjacent structures, sporadic or familial cases, biochemical 
activity, clinical manifestations, morphological character-
istics, response to treatment and recurrence. Although they 
are considered benign tumors, some of them are difficult to 
treat because they can recur after standardized treatment. 
Some studies indicate that trophic and neurotrophic factors 
play a significant role in neuroendocrine systems and in the 
biological effects of molecules involved in the development 
and maintenance of the nervous system. There is some 
evidence suggesting that trophic and neurotrophic factors may 
be involved in pituitary endocrine cell function, suggesting a 
possible role of trophic and neurotrophic factors in the normal 
development of the pituitary gland and in the progression of 
some pituitary adenomas.
The pituitary cells are regulated by endocrine and para-
crine systems through the action of some growth factors and 
their receptors. A different expression and action of these 
factors and their receptors may determine the development 
and progression of pituitary tumors. The vascularization in 
the normal pituitary regulates the growth of pituitary cells 
and the hormone secretion by some molecules: hormones, 
hypothalamic and pituitary growth factors. However, the high 
secretion of EGF, FGF and VEGF in pituitary is involved in 
gland tumorigenesis (159). Generally, the pituitary adenomas 
have a low grade of carcinogenicity. In fact, these tumors are 
rarely aggressive and the angiogenesis is not predominantly 
involved in the improvement of the release of nutrients to the 
tumor. basing upon these reasons, it may be interesting to 
study the possible role of VEGF involved in pituitary angio-
genesis. The development of the vascularization in pituitary 
tumors is less present than in the normal anterior pituitary 
tissue (160,161).
The biological role of these factors in the development and 
progression of this type of tumor should be further investigated 
SPOLETINI et al:  TROPHIC FACTORS IN PITUITARY ADENOMAS 1021
to ameliorate the knowledge of the pathogenesis of pituitary 
adenomas.
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